The medical management of masseteric hypertrophy with botulinum toxin type A

Moore, Austen P; Wood, Geoffrey

doi:10.1016/0266-4356(94)90168-6

Cited by 139 publications

(67 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Complications from surgical excision of masseter include hematoma formation, facial nerve paralysis, infection, mouth opening limitation and sequelae from general anesthesia (3). Injection of botulinum toxin type A into the masseter muscle is first introduced by Smyth, and Moore and Wood in 1994 and considered a less invasive modality and for cosmetic sculpting of the lower face (4,5). Botulinum toxin type A injection is reported to be a safe and effective treatment modality in e650 orofacial dystonies, sialorrhea, frey's syndrome, muscle hypertrophies, etc (6)(7)(8)(9).…”

Section: Introductionmentioning

confidence: 99%

Treatment of masseteric hypertrophy with botulinum toxin: A report of two cases

Baş¹,

Ozan²,

Muğlalı³

et al. 2010

Med Oral

View full text Add to dashboard Cite

Masseter muscle hypertrophy is a rare condition of unknown cause which is important in the differential diagnosis of head and neck masses, located in the cheek. Several treatment options reported for masseter hypertrophy, which range from simple pharmacotherapy to more invasive surgical reduction. Botulinum toxin type A is a powerful neurotoxin which is produced by the anaerobic organism Clostridium botulinum and when injected into a muscle causes interference with the neurotransmitter mechanism producing selective paralysis and subsequent atrophy of the muscle. Injection of botulinum toxin type A into the masseter muscle is generally considered a less invasive modality and has been advocated for cosmetic sculpting of the lower face. Botulinum toxin type A injection is considered to be a beneficial treatment modality in masseter muscle hypertrophy patients. The aim of this article is to report two cases of masseteric muscle hypertrophy which were treated with botulinum toxin type A injection. Marked changes in facial feature were achieved 3 months after the procedure.

show abstract

Section: Introductionmentioning

confidence: 99%

Treatment of masseteric hypertrophy with botulinum toxin: A report of two cases

Baş¹,

Ozan²,

Muğlalı³

et al. 2010

Med Oral

View full text Add to dashboard Cite

show abstract

“…Various clinical trials [55][56][57] reported that injections of BTX into the masseter muscles resulted in a sustained reduction of masseter hyperactivity. With BTX-A injections good, facial contour was achieved [58,59] and several cases were treated successfully [60]. Similarly, temporalis muscle hypertrophy can be treated with BTX injections [61].…”

Section: Masseter Muscle Hypertrophymentioning

confidence: 96%

The Emerging Role of Botulinum Toxin in the Treatment of Orofacial Disorders: Literature Update

Kumar

2017

Asian J Pharm Clin Res

View full text Add to dashboard Cite

Botulinum toxin (BTX) is a lethal neurotoxin produced by Gram-positive anaerobic bacterium called Clostridium botulinum. It is the first toxin used for therapeutic purposes since 1989. BTX treatment is relatively safe and efficacious, less invasive, conservative, and the effects are faster and reversible. The purpose of this article is to review the literature regarding the applications of BTX in the treatment of various orofacial disorders, their mechanism of action, contraindications, and complications. From the recently published literature, it is clear that the role of BTX as a therapeutic agent for several conditions is expanding. With the training of BTX-A injection techniques and adequate knowledge about treatment protocols, general dentists can safely administer BTX injections. The ability to use Botox as an adjuvant and primary mode of the treatment for various maxillofacial disorders offers exciting treatment options for dentists and patients in the future.

show abstract

“…It is, however, necessary to emphasise that it involves a relatively high dose of botulinum toxin to each side of the face at least 3-4 times a year. 17 for a short-term treatment, it is an elegant method, for a long-term treatment the cost becomes expensive. We have no evidence of the long-term effect on the volume reduction and reshaping of the Masseter muscle on the long-term health of the orofacial system.…”

Section: Applications To the Masseter Muscle (Especially Therapy Of Bmentioning

confidence: 99%

Effective applications of botulinum toxin in dentistry and in head and neck surgery

Smucler¹,

Jenča²,

Jenčová³

2017

EDUJ

View full text Add to dashboard Cite

Cite this article:Šmucler R, Jenča A, Jenčova J. Effective applications of botulinum toxin in dentistry and in head and neck surgery. Stoma Edu J. 2017;4(3):200-207.Background: Botulinum toxin A and B is approved for the treatment of many diseases, and we can read many papers experimenting with other possibilities. The use of botulinum toxin is a relatively new option with little or no pre-gradual training in dentistry. Objective: This article aims to summarise current knowledge in this emerging field. Data Sources: A search of MEDLINE, EMBASE, bibliographies of published systematic reviews was performed, as well as of the Cochrane trial registries between 1966 and June 10, 2016. Study Selection: Randomized controlled trials comparing botulinum toxin A with placebo or other interventions were preferred, but for many emerging indication we used non-randomized studies as well to inspire further studies. Data Extraction: Data were abstracted and quality assessed by 1 reviewer. Data Synthesis: We have little-randomised data to quantify the effect of botulinum toxin in a majority of indications in dentistry precisely. Conclusion:The rapid development of the botulinum toxin application brings new possibilities for treatment by dentists alone or in cooperation with other specialists. Besides the above-verified evidencebased indications, there are new and new case studies quickly appearing that need to be monitored and possibly applied. But we have very few randomised studies to make final guidelines in many indications, so further scientific works are really needed. Botulinum toxin should be part of undergraduate and postgraduate teaching.

show abstract

The medical management of masseteric hypertrophy with botulinum toxin type A

Cited by 139 publications

References 10 publications

Treatment of masseteric hypertrophy with botulinum toxin: A report of two cases

Treatment of masseteric hypertrophy with botulinum toxin: A report of two cases

The Emerging Role of Botulinum Toxin in the Treatment of Orofacial Disorders: Literature Update

Effective applications of botulinum toxin in dentistry and in head and neck surgery

Contact Info

Product

Resources

About